Cost-of-illness in neurological diseases in Germany

被引:2
作者
Walbert, T.
Reese, J.-P.
Dodel, R.
机构
[1] Univ Marburg, Neurol Klin, D-35039 Marburg, Germany
[2] Univ Hosp Case Med Ctr, Cleveland, OH USA
关键词
cost-of-illness; neurology; cost; evidence-based; healthcare system;
D O I
10.1055/s-0038-1626857
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The aim of this work is to present a systematic review of German cost-of-illness (COI) studies of neurological diseases. COI studies serve as references for economic evaluations and provide important information to healthcare decision makers in order to allocate resources. A systematic literature review was performed to identify COI studies of neurological diseases and information was extracted by using a standardized assessment form. We found 52 studies that matched the search criteria (multiple sclerosis 6, stroke 11, migraine/headache 6, epilepsy 4, Alzheimer's disease 8, Parkinson's disease 15, dystonia 2). We were not able to retrieve any COI studies for ataxia, vertigo, ALS or CNS-tumours. Based on the literature, no valid German studies are available that would allow a detailed assessment of the economic impact of neurological diseases to society. The reviewed COI studies emphasize the difficulties to present costs, utilities and the use of resources in a transparent way. This information, however, is important to have a rational discussion about the allocation of limited resources in the healthcare systems.
引用
收藏
页码:260 / +
页数:7
相关论文
共 56 条
[21]   Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany [J].
Hamer, Hajo M. ;
Spottke, Annika ;
Aletsee, Christiane ;
Knake, Susanne ;
Reis, Janine ;
Strzelczyk, Adam ;
Oertel, Wolfgang H. ;
Rosenow, Felix ;
Dodel, Richard .
EPILEPSIA, 2006, 47 (12) :2165-2172
[22]  
*HANN KONS, 1999, GES QUAL, pA62
[23]  
HAUSER SL, 1994, HARRISONS PRINCIPLES, P2281
[24]  
Hein T, 2000, NERVENARZT, V71, P288, DOI 10.1007/s001150050559
[25]  
Heinemann LAJ, 1998, NERVENARZT, V69, P1091, DOI 10.1007/s001150050387
[26]  
Jost WH, 2000, J NEUROL, V247, P31
[27]  
Keller S, 2003, NERVENARZT, V74, P1105, DOI 10.1007/s00115-003-1582-6
[28]  
Kleinhenz J, 1990, Offentl Gesundheitswes, V52, P181
[29]   Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis [J].
G. Kobelt ;
L. Jönsson ;
S. Fredrikson .
The European Journal of Health Economics, 2003, 4 (1) :50-59
[30]  
Kobelt G, 2001, Eur J Health Econ, P60